Case Report of Everolimus-Associated DKA in a Patient with Metastatic Renal Cell Carcinoma |
Lee-Kyung Kim1, Chang Ho Ahn1, Jie Eun Lee1, Chan-Hyeon Jung1, Bo Kyung Koo1,2, Min Kyong Moon1,2 |
1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea 2Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea |
전이성 신세포암에서 Everolimus 사용 후 유발된 당뇨병성 케톤산증 1예 |
김이경1, 안창호1, 이지은1, 정찬현1, 구보경1,2, 문민경1,2 |
1서울대학교 의과대학 내과학교실 2서울특별시 보라매병원 내과 |
Correspondence:
Min Kyong Moon, Tel: +82-2-870-2226, Fax: +82-2-831-0714, Email: mkmoon@snu.ac.kr |
Received: 22 December 2013 • Revised: 6 January 2014 • Accepted: 25 February 2014 |
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Abstract |
Everolimus, an inhibitor of the mammalian target of the rapamycin (mTOR) pathway, is widely used as an immunosuppressant for the prevention of organ rejection following transplant and to treat metastatic clear-cell type renal cell carcinoma (RCC), breast cancer, and pancreatic neuroendocrine tumors. Everolimus commonly induces metabolic abnormalities such as hyperglycemia, hypercholesterolemia, and hypertriglyceridemia due to concomitant increases in blood glucose levels via the induction of insulin resistance and a decrease in β cell function, which both lead to insulin deficiency. Although abnormal blood glucose levels are observed in more than 50% of patients treated with Everolimus, hyperglycemia exceeding 500 mg/dL is not common and there have been no reports of Everolimus-induced acute hyperglycemic crisis conditions. Here, a novel case of Everolimus-associated diabetic ketoacidosis (DKA) in a patient with RCC is reported. (Korean J Med 2014;86:761-765) |
Key Words:
Everolimus; DKA; Hyperglycemia; Insulin resistance; Metastatic renal cell carcinoma |
주제어:
Everolimus; 당뇨병성 케톤산증; 고혈당; 인슐린 저항성; 전이성 신세포암 |
|